Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity

Clinical Gastroenterology and Hepatology

Volumn 1, Issue 5, 2003, Pages 384-387

  Shadid, Samyah ^a,b   Jensen, Michael D ^a  

^a MAYO CLINIC   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; THIAZOLIDINE DERIVATIVE;

ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FATTY ACID METABOLISM; FATTY LIVER; FEMALE; HUMAN; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALE; NONALCOHOLIC FATTY LIVER DISEASE; OBESITY; UNITED STATES;

EID: 0141996322     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1053/S1542-3565(03)00198-8     Document Type: Article

References (23)

1. Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2002;4: 31-36.
2. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002;97:2714-2724.
3. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65:166-176.
4. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002;2:11-19.
5. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-226.
6. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000;26:98-106.
7. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
8. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride contents in patients with type 2 diabetes. Diabetes 2002;51:797-802.
9. I underestimation: improved accuracy by a Bayesian two-compartment model. Am J Physiol 1999;277:E481-E488.
10. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667-E677.
11. Kelly IE, Han TS, Walsh K, Lean MEJ. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-293.
12. Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, Tajima N. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy: a randomized controlled trial. Metabolism 2001;50:414-417.
13. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52:1364-1370.
14. Acosta RC, Molina EG, O'Brien CB, Cobo MC, Amaro R, Neff GW, Schiff ER. The use of pioglitazone on nonalcoholic steatohepatitis (abstr). Gastroenterology 2001;120(suppl):A546.
15. Sanyal AJ, Contos MJ, Sargeant C, Stravitz RT, Luketic VA, Sterling RK, Shiffman ML, Mills S. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis (abstr). Hepatology 2002;36(suppl):382A.
16. Promrat K, Lutchman G, Kleiner DE, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Park Y, Yanovski JA, Liang TJ, Hoofnagle JH. Pilot study of pioglitazone in nonalcoholic steatohepatitis (abstr). Gastroenterology 2003;124(suppl):A708.
17. Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPAR-γ) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem Pharmacol 2002;63:1-10.
18. Bedoucha M, Atzpodien E, Boelsterli UA. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001;35:17-23.
19. Moore GB, Chapman H, Holder JC, Lister CA, Piercy V, Smith SA, Clapham JC. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 2001;286:735-741.
20. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 2002;13:18-23.
21. Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA. Mechanisms regulating adipocyte expression of resistin. J Biol Chem 2002; 277:19754-19761.
22. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-2974.
23. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 2002;51: 2895-2902.